Avidity Biosciences
About: Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Employees: 253
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 23
43% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $7.5M
31% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 64
24% more capital invested
Capital invested by funds: $4.66B [Q2] → $5.77B (+$1.11B) [Q3]
23% more funds holding
Funds holding: 196 [Q2] → 241 (+45) [Q3]
11% more funds holding in top 10
Funds holding in top 10: 9 [Q2] → 10 (+1) [Q3]
11.98% less ownership
Funds ownership: 119.33% [Q2] → 107.36% (-11.98%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
RBC Capital Luca Issi 36% 1-year accuracy 21 / 58 met price target | 101%upside $67 | Outperform Reiterated | 21 Jan 2025 |
HC Wainwright & Co. Andrew Fein 37% 1-year accuracy 127 / 343 met price target | 116%upside $72 | Buy Reiterated | 10 Jan 2025 |
Chardan Capital Keay Nakae 26% 1-year accuracy 19 / 74 met price target | 95%upside $65 | Buy Maintained | 13 Nov 2024 |
Needham Joseph Stringer 27% 1-year accuracy 33 / 123 met price target | 80%upside $60 | Buy Reiterated | 13 Nov 2024 |
Financial journalist opinion
Based on 3 articles about RNA published over the past 30 days